Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.98 EUR | +0.86% | +2.09% | -21.90% |
Apr. 25 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 18 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.90% | 837M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+50.07% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
+24.01% | 12.1B |
- Stock Market
- Equities
- FYB Stock
- News Formycon AG
- EU Medicines Regulator Accepts Marketing Authorization Application for Formycon's Biosimilar Candidate